Current and emerging therapies for ocular neovascularisation

Alison L Reynolds; David Kent; Breandán N Kennedy

doi:10.1007/978-1-4614-3209-8_100

Current and emerging therapies for ocular neovascularisation

Adv Exp Med Biol. 2014:801:797-804. doi: 10.1007/978-1-4614-3209-8_100.

Authors

Alison L Reynolds¹, David Kent, Breandán N Kennedy

Affiliation

¹ School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, [email protected].

PMID: 24664773
DOI: 10.1007/978-1-4614-3209-8_100

Abstract

Ocular neovascularisation (ONV) is a pathological feature of many human blinding diseases. Here, we review current pharmacological therapies for these disorders and highlight emerging therapies in clinical trial for ONV. Finally, we discuss desirable characteristics of future ONV therapies, including innovative strategies for novel delivery to the back of the eye.

Publication types

Review

MeSH terms

Animals
Clinical Trials as Topic
Diabetic Retinopathy / drug therapy*
Drug Delivery Systems / methods*
Genetic Therapy / methods*
Humans
Macular Degeneration / drug therapy*
Neovascularization, Pathologic / drug therapy*